Document is current
Any future updates will be listed below
-
Authors
Inagaki, Soichiro
Vaitinadapoule, Hanielle
Yuasa, Taichi
Nakagawa, Tatsuya
Ikegawa, Masaya
Toyama, Yumiko
Nirasawa, Takashi
Tokuda, Yuichi
Nakano, Masakazu
Tashiro, Kei
Tourtas, Theofilos
Schlötzer-Schrehardt, Ursula
Kruse, Friedrich
Aouimeur, Ines
He, Zhiguo
Gain, Philippe
Koizumi, Noriko
Thuret, Gilles
Okumura, Naoki
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (21K06840, 18K09464)
- License Information
-
More Information
Article History
Received: 16 December 2024
Accepted: 24 February 2025
First Online: 26 April 2025
Declarations
:
: Naoki Okumura and Noriko Koizumi are co-founders of ActualEyes Inc., which is currently developing a pharmaceutical therapy for treating Fuchs endothelial corneal dystrophy. However, this affiliation has no influence on the data analysis, results, or conclusions presented in this study. Other authors do not have a competing financial interest.
